Sanofi’s tolebrutinib has been shown to delay disability progression in multiple sclerosis (MS) patients, according to phase ...

Tolebrutinib, a brain-penetrant and bioactive Bruton tyrosine kinase inhibitor that modulates persistent immune activation ...

Sanofi announces tolebrutinib phase 3 study data published in NEJM shows benefit on disability progression in multiple sclerosis: Paris Thursday, April 10, 2025, 10:00 Hrs [IST] T ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

Annual Meeting Clinical Trials Plenary Session, Sanofi presented data on tolebrutinib in patients with non-relapsing ...

Results of the Phase III HERCULES trial suggest the first potential treatment option for a form of multiple sclerosis.

An experimental drug may slow the progression of a form of multiple sclerosis that increases disability relentlessly, a new study finds. There are currently no FDA-approved treatments for ...

AI: For example, advanced diagnostic tests such as CT scans or MRI were more often recommended for high-income patients, ...

The AI models occasionally altered decisions based on patients’ personal characteristics, affecting priority for care and ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Research reveals that AI models may recommend different treatments based on patients’ socioeconomic and demographic profiles, ...

WEDNESDAY, April 9, 2025 (HealthDay News) -- An experimental drug can help patients with advanced multiple sclerosis (MS) ...